Why is AstraZeneca stock down today?

Traders Union
All News
Financial News
Astrazeneca slides 9.37% today

Highlights

AstraZeneca's heart disease drug failed a pivotal trial, triggering a pronounced setback in its development pipeline.
The company ended its HELIOS rare disease study early, but secured new licensing and partnership agreements in oncology and respiratory drugs.
Shares dropped 9.37% amid a 13% downside gap, with bearish technical signals dominating and price expected to remain between GBX11,270 and GBX13,207.

Pipeline setbacks and new deals reshape investor sentiment and strategic focus

AstraZeneca reported that its late-stage trial for a heart disease treatment failed to meet primary endpoints, representing a significant setback in its development pipeline. The company also announced the early termination of its HELIOS rare disease study, but indicated no direct revenue impact. Additionally, AstraZeneca entered a licensing agreement with Sino Biopharmaceutical for ex-China rights to a competitor drug for COPD and advanced negotiations with Daiichi Sankyo regarding the breast cancer therapy Enhertu. An AstraZeneca officer was granted shares under an incentive plan.

Anton Kharitonov, expert at Traders Union, views AstraZeneca’s sharp loss as a clear sign of underlying structural weakness. He notes that repeated trial failures severely damage sentiment, while technical signals confirm persistent bearish momentum. The breakdown below all major moving averages compounds the risk of further losses. Kharitonov highlights that nearly all momentum indicators flash caution or outright bearishness despite short-term buying attempts. "The failed heart disease trial and technical alignment below key moving averages reinforce that buyers should remain defensive until the downtrend is clearly reversed," he says.

Viktoras Karapetjanc, expert at Traders Union, believes the recent AstraZeneca selloff creates long-term opportunity for investors. He sees positive steps in the company’s licensing deals and continued oncology collaborations supporting its innovation pipeline. Karapetjanc is confident that strong fundamentals and strategic moves maintain a bullish structure, even if near-term headlines pressure the stock. He emphasizes that global healthcare demand and robust partnerships offer multiple setups for further growth. "These setbacks are temporary — AstraZeneca’s diversified portfolio and ongoing deals keep the long-term upside well intact," he says.

Parshwa Turakhiya, analyst, notes that AstraZeneca faces increased volatility and conflicting momentum signals after the sudden selloff. He points out potential short-term setups, with prices near support at GBX12,388 and volatility opening trading opportunities for both bulls and bears. Turakhiya observes that mixed momentum indicators and persistent intraday pressure justify a balanced, scenario-driven approach. "I see a tactical range unfolding — traders can expect sharp moves in either direction as volatility remains elevated," he says.

Bearish momentum persists amid mixed signals and heightened volatility

AstraZeneca trades below its 20-day, 50-day, and 200-day moving averages (GBX13,821, GBX13,731, and GBX13,768), indicating persistent downward pressure across short-, medium-, and long-term horizons. Price action remains capped by the Ichimoku Kijun resistance at GBX13,179, with the near-term ceiling at GBX13,107 and support at GBX12,388; the broader moving average alignment confirms a bearish trend backdrop. Momentum signals are mixed: the Moving Average Convergence Divergence (MACD) remains positive, showing underlying buy momentum, yet the Average Directional Index (ADX) and Stochastic RSI signal caution or mild selling pressure. The Relative Strength Index (RSI) and Commodity Channel Index (CCI) both point to a mild buy zone, but Bull/Bear Power (BBP) indicates buyers still dominate intraday action, reaching overbought levels. Awesome Oscillator is neutral. The stock last traded at GBX12,906, down GBX1,334 or 9.37% after opening with a pronounced downside gap of about 13% and now sits near the intraday high with volatility at 5.81%. Intraday tone is volatile with pressure after the open, and divergences in momentum indicators add uncertainty to near-term direction.

Previously it was reported that AstraZeneca faced heightened selling pressure after its late-stage heart disease trial failed to meet key endpoints, triggering concerns over its development pipeline. The current setup not only reinforces persistent bearish momentum but also introduces additional pipeline challenges, making GBX12,388 a critical level to monitor for directional shifts in the near term.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.